Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Cholangiocarcinoma 2Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 11Specimen Handling 8X-Rays 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6olaparib 4ulixertinib 3trametinib 3palbociclib 3larotrectinib 3ivosidenib 3erdafitinib 3dabrafenib 3Vemurafenib 3tipifarnib 2tazemetostat 2selpercatinib 2ensartinib 2durvalumab 2Nivolumab 2LY3023414 2Gemcitabine 2Doxorubicin 2Docetaxel 2Cisplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × olutasidenib × Gastrointestinal × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡